The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thanks for sharing the useful insight as usual Viveka. The MTX110 data is definitely overdue, they did add some extra cohorts at higher doses that were initially planned, which I see as good news. There has also been COVID - 19, which seems to be delaying many oncology studies and related procedures. Nonetheless it would help if we had an update.
Nonetheless, independently of maths, today's price must hurt for those who bought in at 87p. I bought my first bunch of shares here in 2015 for a bit over £2.75 (that's now over £55 per share when you factor in the recent reverse split of 20 to 1). I averaged down over time and managed to sell a few spikes ago to break even. In more recent times I've even made a profit after buying back in. Anyways just hold on for the next spike or even stable upwards price adjustment (if we are lucky). This share is now so volatile I'd be surprised if we don't see another spike soon. It also has good tech and a fair chance of making some money now so isn't a bad investment either.
Dragon, this share will rocket on average or no news simply due to speculation (like the spike before last, which the CEO issued a speeding ticket for). Also HMS Midatech appears to be a leaky ship and you often see the SP start to rise sharply AHEAD of an RNS, which is a bit naughty but a fact and gets people excited so more pile in. This is a tricky beast.
I don't think that MTPH will drop the US side. Being listed on the NASDAQ allows the company to raise funds in the US (raising in the UK is much more difficult). Stamp even admitted this himself on one of the company webcasts. Without this emergency life support facility the company would probably have gone belly up some time ago.....
WOW, have LSE applied some pest control, the board is readable again (for the mean time anyway)!?
Not sure if news tomorrow but we should get an update from the Dr. Reddy's collaboration soon. The potential collaboration news was released on the 8th June and it should only take a couple of months to evaluate the tech via experiments so news could be pretty soon. I'm betting on it being positive news but it's only a bet and I'm well aware I might be developing a gambling problem with this share. What makes me more confident is that the Co. has built up a significant volume of data that the Q-Sphera tech works, some of it in the clinic. Hopefully this will apply to what Dr. Reddy's has in mind.
FYI there is a filter on this board that can be used to get rid of any unwanted noise. It makes finding those more valuable posts that more easy.
Timmy, your advice is spot on, especially with MTPH. I've been caught out more than once with this share but managed to stay above water overall. Poor liquidity and SP spikes make this a difficult beast to tame.
"With this share it is If you are going to average down, I'd reccomend waiting for the price to settle. 'Never try to catch a falling knife', as they say... There's a good chance that in the absence of further news this could return to the pre-rns levels (or maybe settle slightly higher). Also I'd say don't average down if it means you're overexposing yourself; this is a pretty risky share"
A merger with Emergex would obviously be great Viveka. Obviously speculative but the recent activity might flush them out as they need our tech. Could get interesting!
Thanks Viveka, makes sense in that context and less concerning. I hope things move quickly for the sake of the Co. and us shareholders!
Great summary as usual Viveka. I'm hoping one of the inflection points you mention produce news soon. I fear the SP will erode further without it. I suspect we should hear about Dr. Reddy's soonish? I am a bit concerned about the removal of the company's 'for sale' sign, do you think this is this part of the MTX110 Secura Bio issue? If so does not sound as cut and dry as I thought.
Based on the last few years experience of this share, without further news unfortunately we could go back down to around pre-RNS SP. Really hope not but can't ignore what keeps on repeating itself. Once you do see the pattern it can be quite profitable. GLA.
This rise is due to the most recent RNS i.e. a pharma company is assessing the Q sphera tech and will decide if they want to use it for their drugs. It would be a royalty only deal for MTPH. Positive news but anyone who knows this share well will have seen this type of price spike before off of average or even no news. I'm certainly not complaining. As for the takeover, it's anyone's guess as to if and who.
I remember that exchange Viveka only because it seemed an odd comment from 'themarketseer'. It makes more sense now. I don't usually take the conspiracy theorist's approach but in this case may be an exception. Did Secure Bio really approach Midatech without engaging legal. They must have known full well of the implications of their letter. There seem to be some pretty obvious holes on their approach that even a layman can detect. Logic would suggest foul play.
I hear you Rosie with the legal interpretation and it's wise to question. I've seen up called down before by lawyers and it get swallowed! In this case they will have a very hard time. The insolvency act 1986 makes good bedtime reading if you are that way inclined....
Rosie I don't think we don't need a corporate lawyer - the restructuring RNS clearly states partnering OR selling assets in part OR full sale of company. That does not fit the definition of a liquidation in any form. Also MTX110 is currently in R&D clinical trials so R&D has definitely not stopped. I smell a rat here.
On the face of it this looks like a mistake (quite a costly mistake for Secura Bio if they push this as MTPH will quite rightly sue) BUT I wouldn't rule out some mischievous antics going on here.
I think this is good news but it won't be reflected in the SP until we see more specifics around how the tech is going to be used. Dr. Reddy's is originally an Indian generics company but with more recently a global reach into most markets. Years ago I can remember there being issues over manufacturing quality and patent infringement. I think most of that is behind them and a credible company with aspirations to reformulate and improve existing drugs has emerged. Dr. Reddy's has much deeper pockets than Midatech so if they bite then really good things could happen. Like others I really see this as a 'try before you buy' announcement' but it's the best news we have had for a long time.
I agree NicetoMichu, there have been many low body blows over the long term. I've done ok recently with recouping losses through short term trading up until now. This most recent sneaky kidney punch has put me back underwater as I really didn't see it coming, I stupidly assumed that the company announcing it was selling off some or all of its assets didn't mean a raise was coming. That's my bad, I should have known better, trading short term on this share is no better than gambling.
Viveka - I didn't think this company could be any more unscrupulous.... Apparently I was wrong. I was thinking exactly the same thing as you, why is more money needed to bolster outlicencing / partnering when they have MTD-201 sitting on the shelf begging for the same? I know they have MTX-110 ongoing int the clinic but the money already in hand should have been enough to see them through short-mid term given the recent consolidation. I can only think that this is a play to simply limp on a bit further past the worst of COVID-19 and then sell after trying to add more value? Let's face it this isn't exactly the optimal time to get a good deal selling the company in the middle of a global pandemic.